(NASDAQ:AMAT), SANTA CLARA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that it will hold its fourth quarter and fiscal 2025 earnings conference call on Thursday, Nov. 13, 2025, at 4:30 p.m. ET / 1:30 p.m. PT. The call will be webcast live at: https://ir.appliedmaterials.com. A replay will be available on […]
(TSX:GUD), MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI(R) in Argentina. Knight obtained approval from the Argentinian health regulatory agency, ANMAT, for MINJUVI(R) (tafasitamab) in combination
(TSX:GUD), MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2025 financial results on Thursday, November 6, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties
(NYSE:DTM), DETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) — DT Midstream, Inc. (NYSE: DTM) today announced third quarter 2025 reported net income of $115 million, or $1.13 per diluted share. For the third quarter of 2025, Operating Earnings were also $115 million, or $1.13 per diluted share. Adjusted EBITDA for the quarter was $288 million. Reconciliations
(NASDAQ:FXNC), STRASBURG, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) — First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported earnings for the quarter ended September 30, 2025, of $5.55 million and basic and diluted earnings per common share of $0.62. “We are pleased to report
GLEN COVE, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) — Epicured Inc., the leading provider of medically tailored nutrition solutions and preferred nutrition partner supporting clinical research with standardized, protocol-aligned meals for pharmacokinetic and pharmacodynamic studies, has appointed Patricia Bradley as its Senior Vice President, Life Sciences and Clinical Development Partnerships. In this role, Bradley will
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline Agreement combines Turn's PermaFusion(R) delivery platform with Medline's global scale and distribution capabilities to advance professional and retail product opportunities GlobeNewswire October 30, 2025 WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics (Nasdaq: TTRX) (“Turn”
Lancaster Resources LiDAR Results and Field Trip Data from Lake Cargelligo Gold Project GlobeNewswire October 30, 2025 VANCOUVER, British Columbia, Oct. 30, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF) (“Lancaster” or the “Company“) reports new LiDAR and field data analysis revealing multiple gold-bearing targets and previously unmapped vein systems at its
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs GlobeNewswire October 30, 2025 – Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors – Selective CBP degrader is on
Digi Power X to Announce 2025 Q3 Financial Results on November 13th GlobeNewswire October 30, 2025 This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) — Digi